Biomarker tools to Design Clinical Vaccines Determined from a study of annual Listeriosis Incidence in Northern spain

Ver/Abrir
Identificadores
URI: http://hdl.handle.net/10902/12997
ISSN: 1664-3224
Compartir
Estadísticas
Ver Estadísticas
Google Scholar
Registro completo
Mostrar el registro completo DC
Autoría
Calderón González, Ricardo; Terán Navarro, Héctor; Marimon, José María; González Rico, Claudia; Calvo Montes, Jorge; Frande Cabanes, Elisabet; Alkorta Gurrutxaga, Miriam; Fariñas Álvarez, María del CarmenAutoridad Unican; Martínez Martínez, LuisAutoridad Unican; Pérez Trallero, Emilio; Álvarez Domínguez, CarmenAutoridad Unican
Fecha
2016-11
Derechos
© 2016 Calderon-Gonzalez, Teran-Navarro, Marimon, González-Rico, Calvo-Montes, Frande-Cabanes, Alkorta-Gurrutxaga, Fariñas, Martínez-Martínez, Perez-Trallero and Alvarez-Dominguez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). This Document is protected by Copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.
Publicado en
Front. Immunol. Nov 2016 7:541
Editorial
Frontiers Research Foundation
Resumen/Abstract
Two regions of northern Spain, Gipuzkoa, and Cantabria present high annual incidence of listeriosis (1.86 and 1.71 cases per 100,000 inhabitants, respectively). We report that the high annual incidences are a consequence of infection with highly virulent Listeria monocytogenes isolates linked to fatal outcomes in elderly patients with cancer. In addition, listeriosis patients with cancer present low IL-17A/IL-6 ratios and significantly reduced levels of anti-GAPDH1?22 antibodies, identified as two novel biomarkers of poor prognosis. Analysis of these biomarkers may aid in reducing the incidence of listeriosis. Moreover, GAPDH1?22-activated monocyte-derived dendritic cells of listeriosis patients with cancer seem useful tools to prepare clinical vaccines as they produce mainly Th1 cytokines.
Colecciones a las que pertenece